News | Atrial Fibrillation | January 31, 2020

Medtronic FDA Trial Evaluates Pulsed Electric Fields to Treat Atrial Fibrillation

Investigative new energy source technology designed to interrupt irregular pathways in the heart

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.


January 31, 2020 – The U.S. Food and Drug Administration (FDA) has given Medtronic approval to proceed with an investigational device exemption (IDE) trial to evaluate the safety and effectiveness of the PulseSelect Pulsed Field Ablation (PFA) System. This new technology that uses pulsed electric fields to treat atrial fibrillation (Afib or AF). 

The first procedures in the trial were recently performed. In December 2019 by Bradley Wilsmore, M.D., at John Hunter Hospital, New Lambton Heights, NSW, Australia, and in January by Atul Verma, M.D., the principal investigator (PI) for the study, at Southlake Regional Health Centre in Newmarket, Canada.

 

Pulsed Field Ablation Technology

PFA uses pulsed electric fields to ablate or create lesions and scar tissue to interrupt irregular electrical pathways in the heart and the triggers of atrial fibrillation. However, unlike traditional methods of ablation that heat the tissue (radio frequency) or cool the tissue (cryo) to ablate, PFA is non-thermal and selectively targets cardiomyocytes (heart muscle cells) while avoiding other types of tissue.

“This study will evaluate a new energy source that may treat atrial fibrillation and potentially address the risks that have been associated with other ablation technologies, such as unintended tissue damage,” Verma said. “The rigorous pre-clinical research to get us to these first procedures has been impressive and we are excited to support the development of more clinical evidence.”

In September 2018, Medtronic was granted breakthrough device designation from the FDA for the PFA technology for the treatment of drug refractory recurrent symptomatic atrial fibrillation. Worldwide, the PFA system is investigational and not approved for sale or distribution. 

The PULSED AF Trial 

PULSED AF study is a prospective, multi-center, non-randomized, unblinded and worldwide trial that will enroll patients who will be treated with the Medtronic PulseSelect PFA System.

“As a global leader in the treatment of cardiac arrhythmias, Medtronic is constantly evaluating new and existing therapies to better meet the needs of patients and the physicians who care for them,” said Rebecca Seidel, vice president and general manager in the AF solutions division, which is part of the Cardiac and Vascular Group at Medtronic. “The PULSED AF study is another example of our commitment to meaningful innovation and a major step forward in the development of a diverse set of therapy options for atrial fibrillation patients.”

For more information: www.medtronic.com

 

Related Pulse Electric Field Ablation Content:

First-in-human Electroporation Ablation Study Finds Pulsed Electric Fields Can Target Specific Tissue For Atrial Fibrillation

Boston Scientific Invests in Pulsed Field Ablation Technology To Improve Atrial Fibrillation Therapy

Pulsed AF Trial Shows Pulsed Field Ablation May be Safer Than Traditional RF Ablations

First Patients Treated with Galaxy Medical Centauri Pulsed Electric Field Cardiac Ablation System


Related Content

News | Atrial Fibrillation

June 13, 2025 — An international study has shown that targeted online education on atrial fibrillation (AF) for health ...

Home June 16, 2025
Home
News | Atrial Fibrillation

May 21, 2025 — Corify Care recently announced it has entered into a know-how agreement with Mayo Clinic. Corify Care is ...

Home May 22, 2025
Home
News | Atrial Fibrillation

April 25, 2025 – Medtronic plc, a global leader in healthcare technology, recently received U.S. Food and Drug ...

Home April 29, 2025
Home
News | Atrial Fibrillation

April 27, 2025 – The Heart Rhythm Society (HRS) has announced the findings of new studies demonstrating the safety and ...

Home April 28, 2025
Home
News | Atrial Fibrillation

April 24, 2025 – The Heart Rhythm Society (HRS) has unveiled new research that underscores the critical role of ...

Home April 25, 2025
Home
News | Atrial Fibrillation

April 23, 2025 – The Heart Rhythm Society (HRS) has released a framework outlining criteria for establishing an Atrial ...

Home April 23, 2025
Home
News | Atrial Fibrillation

April 7, 2025 — CardioVia, a medical device company specializing in advanced cardiac care solutions, has received U.S ...

Home April 08, 2025
Home
News | Atrial Fibrillation

March 29, 2025 — Anthos Therapeutics, Inc., presented two new analyses from its AZALEA-TIMI 71 study at the American ...

Home March 31, 2025
Home
News | Atrial Fibrillation

Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrial ...

Home March 12, 2025
Home
News | Atrial Fibrillation

March 1, 202 — One in three people worldwide will develop a potentially life-threatening heart rhythm disorder in their ...

Home March 03, 2025
Home
Subscribe Now